Sign Of Normalcy? US FDA Schedules Meeting But Pauses Non-COVID Guidance Development
As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.
You may also be interested in...
The move is intended to streamline virtual advisory committee meetings, FDA official says.
OTC Decisions In May: Esomeprazole For Sun Pharma, Guaifenesin For Granules India, More NRTs For PLD During Slow Month For Approvals
CDER representative says staff’s time available for drug applications currently is affected by the FDA having employees work remotely in response to the novel coronavirus pandemic.
The US agency had planned to hold an in-person meeting of its ophthalmic advisory committee in early June, indicating hope that things would be back to some form of normal by then. But due to the ongoing coronavirus pandemic, it has postponed that meeting until further notice.